Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emricasan in mild COVID-19 outpatients
NCT04803227Phase 1Terminated
- Sponsor
- Histogen Inc.
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Emricasan with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events at 14 Days. Started Mar 2021; status: terminated.
02
Drugs
emricasan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04803227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803227.